The Federal Bureau of Investigation is trying to unmask the operator of Archive.is, also known as Archive.today, a website that saves snapshots of webpages and is commonly used to bypass news paywalls.

The FBI sent a subpoena to domain registrar Tucows, seeking “subscriber information on [the] customer behind archive.today” in connection with “a federal criminal investigation being conducted by the FBI.” The subpoena tells Tucows that “your company is required to furnish this information.”

The subpoena is supposed to be secret, but the Archive.today X account posted the document on October 30, the same day the subpoena was issued. The X post contained a link to the PDF and the word “canary.”

Read full article

Comments

The Federal Bureau of Investigation is trying to unmask the operator of Archive.is, also known as Archive.today, a website that saves snapshots of webpages and is commonly used to bypass news paywalls.

The FBI sent a subpoena to domain registrar Tucows, seeking “subscriber information on [the] customer behind archive.today” in connection with “a federal criminal investigation being conducted by the FBI.” The subpoena tells Tucows that “your company is required to furnish this information.”

The subpoena is supposed to be secret, but the Archive.today X account posted the document on October 30, the same day the subpoena was issued. The X post contained a link to the PDF and the word “canary.”

Read full article

Comments

The Federal Bureau of Investigation is trying to unmask the operator of Archive.is, also known as Archive.today, a website that saves snapshots of webpages and is commonly used to bypass news paywalls.

The FBI sent a subpoena to domain registrar Tucows, seeking “subscriber information on [the] customer behind archive.today” in connection with “a federal criminal investigation being conducted by the FBI.” The subpoena tells Tucows that “your company is required to furnish this information.”

The subpoena is supposed to be secret, but the Archive.today X account posted the document on October 30, the same day the subpoena was issued. The X post contained a link to the PDF and the word “canary.”

Read full article

Comments

At a White House event Thursday, President Trump announced deals with drug makers Novo Nordisk and Eli Lilly to offer their popular GLP-1 obesity and diabetes drugs at lower prices for some Americans, namely some on Medicare and Medicaid plans. But questions linger about the significance of the deal.

According to the announcement , Medicare and state Medicaid programs will be able to purchase a month’s supply of Ozempic, Wegovy, Mounjaro, and Zepbound at $245 each for eligible patients. Eligible people on Medicare will have a $50 co-pay for them.

The negotiated price is a significant cut from the drugs’ list prices: The list price for Ozempic is $997; Wegovy is $1,350; Mounjaro is $1,080; and Zepbound is $1,086. But, of course, purchasers rarely pay drug list prices. It’s unclear how much Medicare and Medicaid would have paid for the drugs without this deal and what the savings will be.

Read full article

Comments

At a White House event Thursday, President Trump announced deals with drug makers Novo Nordisk and Eli Lilly to offer their popular GLP-1 obesity and diabetes drugs at lower prices for some Americans, namely some on Medicare and Medicaid plans. But questions linger about the significance of the deal.

According to the announcement , Medicare and state Medicaid programs will be able to purchase a month’s supply of Ozempic, Wegovy, Mounjaro, and Zepbound at $245 each for eligible patients. Eligible people on Medicare will have a $50 co-pay for them.

The negotiated price is a significant cut from the drugs’ list prices: The list price for Ozempic is $997; Wegovy is $1,350; Mounjaro is $1,080; and Zepbound is $1,086. But, of course, purchasers rarely pay drug list prices. It’s unclear how much Medicare and Medicaid would have paid for the drugs without this deal and what the savings will be.

Read full article

Comments

At a White House event Thursday, President Trump announced deals with drug makers Novo Nordisk and Eli Lilly to offer their popular GLP-1 obesity and diabetes drugs at lower prices for some Americans, namely some on Medicare and Medicaid plans. But questions linger about the significance of the deal.

According to the announcement , Medicare and state Medicaid programs will be able to purchase a month’s supply of Ozempic, Wegovy, Mounjaro, and Zepbound at $245 each for eligible patients. Eligible people on Medicare will have a $50 co-pay for them.

The negotiated price is a significant cut from the drugs’ list prices: The list price for Ozempic is $997; Wegovy is $1,350; Mounjaro is $1,080; and Zepbound is $1,086. But, of course, purchasers rarely pay drug list prices. It’s unclear how much Medicare and Medicaid would have paid for the drugs without this deal and what the savings will be.

Read full article

Comments

For months, extremely personal and sensitive ChatGPT conversations have been leaking into an unexpected destination: Google Search Console (GSC), a tool that developers typically use to monitor search traffic, not lurk private chats.

Normally, when site managers access GSC performance reports, they see queries based on keywords or short phrases that Internet users type into Google to find relevant content. But starting this September, odd queries, sometimes more than 300 characters long, could also be found in GSC. Showing only user inputs, the chats appeared to be from unwitting people prompting a chatbot to help solve relationship or business problems, who likely expected those conversations would remain private.

Jason Packer, owner of an analytics consulting firm called Quantable, was among the first to flag the issue in a detailed blog last month.

Read full article

Comments

For months, extremely personal and sensitive ChatGPT conversations have been leaking into an unexpected destination: Google Search Console (GSC), a tool that developers typically use to monitor search traffic, not lurk private chats.

Normally, when site managers access GSC performance reports, they see queries based on keywords or short phrases that Internet users type into Google to find relevant content. But starting this September, odd queries, sometimes more than 300 characters long, could also be found in GSC. Showing only user inputs, the chats appeared to be from unwitting people prompting a chatbot to help solve relationship or business problems, who likely expected those conversations would remain private.

Jason Packer, owner of an analytics consulting firm called Quantable, was among the first to flag the issue in a detailed blog last month.

Read full article

Comments

For months, extremely personal and sensitive ChatGPT conversations have been leaking into an unexpected destination: Google Search Console (GSC), a tool that developers typically use to monitor search traffic, not lurk private chats.

Normally, when site managers access GSC performance reports, they see queries based on keywords or short phrases that Internet users type into Google to find relevant content. But starting this September, odd queries, sometimes more than 300 characters long, could also be found in GSC. Showing only user inputs, the chats appeared to be from unwitting people prompting a chatbot to help solve relationship or business problems, who likely expected those conversations would remain private.

Jason Packer, owner of an analytics consulting firm called Quantable, was among the first to flag the issue in a detailed blog last month.

Read full article

Comments